Serum levels of reactive oxygen metabolites at 12 weeks during tocilizumab therapy are predictive of 52 weeks-disease activity score-remission in patients with rheumatoid arthritis

BACKGROUND: To verify whether serum levels of reactive oxygen metabolites (ROM) are predictive of future clinical remission in patients with rheumatoid arthritis (RA) receiving tocilizumab (TCZ) therapy. METHODS: A total of 46 patients with RA receiving TCZ therapy were enrolled in this study. Patie...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Rheumatol
Autori principali: Nakajima, Arata, Terayama, Keiichiro, Sonobe, Masato, Aoki, Yasuchika, Takahashi, Hiroshi, Akatsu, Yorikazu, Saito, Junya, Taniguchi, Shinji, Yamada, Manabu, Kubota, Ayako, Nakagawa, Koichi
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2019
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6912997/
https://ncbi.nlm.nih.gov/pubmed/31891116
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s41927-019-0096-1
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi